Of the 51 patients who received CD19+ CAR T-cells during the specified period, 34 (68%) developed hyponatremia post infusion (Table 2), and 29 (57%) patients had a decrease in Na > 7 mEq/L post infusion. The gene discussed is CD19; the disease is Hyponatremia.